A Phase 1 interventional study of Aramchol free acid tablet 600mg, single dose and Aramchol free acid tablet 300mg, bid in Hepatic Impairment, sponsored by Galmed Research and Development, Ltd.. Completed at 3 sites in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-14.
Sponsored by Galmed Research and Development, Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Phase 1, multicenter, open-label, 2-part, single- and multiple-dose study designed to assess the effect of hepatic insufficiency on the PK of aramchol
Each of the 2 parts of the study consisted of a screening period, a check in day, a treatment period, and an end of study (EOS) visit.
In Part 1 (single-dose): 39 subjects were enrolled: 8 subjects each in the mild (Cohort A), moderate (Cohort B), and severe (Cohort C) hepatic impairment cohorts and 15 healthy control subjects with normal hepatic function (Cohort D). Enrollment of 8 subjects with mild hepatic impairment (Cohort A) proceeded only if there is evidence of reduced clearance of aramchol in Cohort B. Assignment to cohorts A to C, was according to Child Pugh classification system.
Serial blood samples for PK analysis of aramchol concentrations in plasma were collected before dosing (0 hour) and up to 168 hours for healthy subjects and 240 hours for hepatically impaired subjects after administration of aramchol.
In Part 2 (multiple-dose), a cohort of 4 subjects comprising of mild, 7 moderate , as well as a cohort of 7 healthy volunteers was administered with aramchol as multiple doses to obtain the PK profile of aramchol at steady state. Aramchol was given twice daily for 12 days. Trough blood samples for analysis of aramchol plasma concentrations was collected before the AM dose on several days and at intervals to 12 hours after the AM dose on Day 12.
Galmed Research and Development, Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subject is able to provide written .
Additional Inclusion Criteria for Healthy Subjects Only (Cohort D):
The subject is judged by the investigator to be in good general health, as determined by medical history, clinical laboratory assessments, vital sign measurements, 12 lead (ECG) results, and physical examination findings.
Additional Inclusion Criteria for Subjects With Hepatic Impairment Only (Cohorts A, B, and C):
Exclusion Criteria:
For additional exclusion criteria specific to hepatic impaired subjects and healthy volunteers, see protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
8 mild hepatic impaired subjects
Drug: Aramchol free acid tablet 600mg, single dose
8 moderate hepatic impaired subjects
Drug: Aramchol free acid tablet 600mg, single dose
8 severe hepatic impaired subjects
Drug: Aramchol free acid tablet 600mg, single dose
15 matched healthy volunteers
Drug: Aramchol free acid tablet 600mg, single dose
4 mild hepatic impaired subjects
Drug: Aramchol free acid tablet 300mg, bid
7 moderate hepatic impaired subjects
Drug: Aramchol free acid tablet 300mg, bid
7 matched healthy volunteers
Drug: Aramchol free acid tablet 300mg, bid
Aramchol free acid tablet 600mg, single dose
Also known as: Cholan-24-oic acid 7,12-dihydroxy3-[(1- oxoeicosyl)amino]-(3β,5β,7α,12α) salt with N-methyl-(D)-glucamine
Aramchol acid tablet 300mg, bid for 12 days
Also known as: Cholan-24-oic acid 7,12-dihydroxy3-[(1- oxoeicosyl)amino]-(3β,5β,7α,12α) salt with N-methyl-(D)-glucamine
AUC0-tau, Steady State
AUC from time 0 to the dosing interval tau measured at steady state. Blood was collected at the following time points: before dosing (0 hour) and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 48, 72, 96, 120, 144, 168, 192, and 240 hours
Time frame: Day 12
Cmax,ss
Maximum plasma concentrations (Cmax,ss) Blood was collected at the following time points: before dosing (0 hour) and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 48, 72, 96, 120, 144, 168, 192, and 240 hours
Time frame: Day 12
Apparent Total Oral Clearance, Single Dose
CL/F measured after single dose in Part 1 Blood was collected at the following time points: before dosing (0 hour) and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 48, 72, 96, 120, 144, 168, 192, and 240 hours
Time frame: Day 11
Number of Subjects With Significant TEAEs
The number of significant treatment-related adverse events
Time frame: Part 1: up to 22 days; Part 2: up to 27 days
| Milestone | Part 1: Mild Hepatic Impairment (Cohort A) | Part 1: Moderate Hepatic Impairment (Cohort B) | Part 1: Severe Hepatic Impairment (Cohort C) | Part 1: Healthy Volunteers (Cohort D) | Part 2: Mild Hepatic Impairment Cohort | Part 2- Moderate Hepatic Impairment Cohort | Part 2: Healthy Volunteers Cohort |
|---|---|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 15 | 4 | 7 | 7 |
| Completed | 8 | 8 | 8 | 15 | 4 | 6 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
AUC from time 0 to the dosing interval tau measured at steady state. Blood was collected at the following time points: before dosing (0 hour) and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 48, 72, 96, 120, 144, 168, 192, and 240 hours
| h•ng/mL | Part 1: Mild Hepatic Impairment (Cohort A) | Part 1: Moderate Hepatic Impairment (Cohort B) | Part 1: Severe Hepatic Impairment (Cohort C) | Part 1: Healthy Volunteers (Cohort D) | Part 2: Mild Hepatic Impairment Cohort | Part 2: Moderate Impairment Cohort | Part 2: Healthy Volunteers Cohort |
|---|---|---|---|---|---|---|---|
| AUC0-tau, Steady State | 96100 ± 138.29 | 107000 ± 154.13 | 103000 ± 148.09 | 69500 ± 0 | 63300 ± 4.3 | 55900 ± 31.4 | 61400 ± 26 |
Maximum plasma concentrations (Cmax,ss) Blood was collected at the following time points: before dosing (0 hour) and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 48, 72, 96, 120, 144, 168, 192, and 240 hours
| ng/mL | Part 1: Mild Hepatic Impairment (Cohort A) | Part 1: Moderate Hepatic Impairment (Cohort B) | Part 1: Severe Hepatic Impairment (Cohort C) | Part 1: Healthy Volunteers (Cohort D) | Part 2: Mild Hepatic Impairment Cohort | Part 2: Moderate Hepatic Impairment Cohort | Part 2: Healthy Volunteers Cohort |
|---|---|---|---|---|---|---|---|
| Cmax,ss | 1950 ± 138.17 | 1890 ± 134.26 | 1480 ± 105.22 | 1410 ± 0 | 5750 ± 5.2 | 5380 ± 26.1 | 6040 ± 21.3 |
CL/F measured after single dose in Part 1 Blood was collected at the following time points: before dosing (0 hour) and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 48, 72, 96, 120, 144, 168, 192, and 240 hours
| L/h | Part 1: Mild Hepatic Impairment (Cohort A) | Part 1: Moderate Hepatic Impairment (Cohort B) | Part 1: Severe Hepatic Impairment (Cohort C) | Part 1: Healthy Volunteers (Cohort D) | Part 2: Mild Hepatic Impairment Cohort | Part 2: Moderate Impairment Cohort | Part 2: Healthy Volunteers Cohort |
|---|---|---|---|---|---|---|---|
| Apparent Total Oral Clearance, Single Dose | 5.96 ± 43.8 | 5.23 ± 29.2 | 5.86 ± 52.5 | 8.01 ± 50.1 | — | — | — |
The number of significant treatment-related adverse events
| Participants | Part 1: Mild Hepatic Impairment (Cohort A) | Part 1: Moderate Hepatic Impairment (Cohort B) | Part 1: Severe Hepatic Impairment (Cohort C) | Part 1: Healthy Volunteers (Cohort D) | Part 2: Mild Hepatic Impairment Cohort | Part 2: Moderate Hepatic Impairment Cohort | Part 2: Healthy Volunteers Cohort |
|---|---|---|---|---|---|---|---|
| Number of Subjects With Significant TEAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Adverse events were assessed from the time the subject signed the informed consent until study completion (i.e., End of study- 30 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Mild Hepatic Impairment (Cohort A) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Part 1: Moderate Hepatic Impairment (Cohort B) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Part 1: Severe Hepatic Impairment (Cohort C) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Part 1: Healthy Volunteers (Cohort D) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Part 2: Mild Hepatic Impairment Cohort | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Part 2: Moderate Impairment Cohort | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Part 2: Healthy Volunteers Cohort | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
| Event | Part 1: Mild Hepatic Impairment (Cohort A) | Part 1: Moderate Hepatic Impairment (Cohort B) | Part 1: Severe Hepatic Impairment (Cohort C) | Part 1: Healthy Volunteers (Cohort D) | Part 2: Mild Hepatic Impairment Cohort | Part 2: Moderate Impairment Cohort | Part 2: Healthy Volunteers Cohort |
|---|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/8 | 0/8 | 0/8 | 0/15 | 0/4 | 1/7 | 0/7 |
Population in Part 1 included mild hepatic impairment subjects, moderate hepatic impairment subjects, severe hepatic subjects, and healthy matched control subjects. Population in Part 2 included mild hepatic impairment subjects, moderate hepatic impairment subjects, and healthy matched control subjects.
| Age, Categorical(Participants) | Part 1: Mild Hepatic Impairment (Cohort A) | Part 1: Moderate Hepatic Impairment (Cohort B) | Part 1: Severe Hepatic Impairment (Cohort C) | Part 1: Healthy Volunteers (Cohort D) | Part 2: Mild Hepatic Impairment Cohort | Part 2: Moderate Hepatic Impairment Cohort | Part 2: Healthy Volunteers Cohort | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 5 | 5 | 10 | 2 | 4 | 6 | 39 |
| >=65 years | 1 | 3 | 3 | 5 | 2 | 3 | 1 | 18 |
| Age, Continuous(Years) | Part 1: Mild Hepatic Impairment (Cohort A) | Part 1: Moderate Hepatic Impairment (Cohort B) | Part 1: Severe Hepatic Impairment (Cohort C) | Part 1: Healthy Volunteers (Cohort D) | Part 2: Mild Hepatic Impairment Cohort | Part 2: Moderate Hepatic Impairment Cohort | Part 2: Healthy Volunteers Cohort | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 59.1 ± 8.10 | 63.3 ± 9.02 | 62.0 ± 6.35 | 59.7 ± 8.50 | 64.0 ± 4.16 | 60.1 ± 8.47 | 60.1 ± 6.82 | 60.86 ± 7.63 |
| Sex: Female, Male(Participants) | Part 1: Mild Hepatic Impairment (Cohort A) | Part 1: Moderate Hepatic Impairment (Cohort B) | Part 1: Severe Hepatic Impairment (Cohort C) | Part 1: Healthy Volunteers (Cohort D) | Part 2: Mild Hepatic Impairment Cohort | Part 2: Moderate Hepatic Impairment Cohort | Part 2: Healthy Volunteers Cohort | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 1 | 3 | 4 | 4 | 1 | 1 | 2 | 16 |
| Male | 7 | 5 | 4 | 11 | 3 | 6 | 5 | 41 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Mild Hepatic Impairment (Cohort A) | Part 1: Moderate Hepatic Impairment (Cohort B) | Part 1: Severe Hepatic Impairment (Cohort C) | Part 1: Healthy Volunteers (Cohort D) | Part 2: Mild Hepatic Impairment Cohort | Part 2: Moderate Hepatic Impairment Cohort | Part 2: Healthy Volunteers Cohort | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 4 | 1 | 1 | 1 | 3 | 3 | 13 |
| Not Hispanic or Latino | 8 | 4 | 7 | 14 | 3 | 4 | 4 | 44 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: Mild Hepatic Impairment (Cohort A) | Part 1: Moderate Hepatic Impairment (Cohort B) | Part 1: Severe Hepatic Impairment (Cohort C) | Part 1: Healthy Volunteers (Cohort D) | Part 2: Mild Hepatic Impairment Cohort | Part 2: Moderate Hepatic Impairment Cohort | Part 2: Healthy Volunteers Cohort | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Asian | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 0 | 3 | 1 | 0 | 1 | 7 |
| White | 5 | 8 | 8 | 10 | 2 | 7 | 6 | 46 |
| More than one race | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part 1: Mild Hepatic Impairment (Cohort A) | Part 1: Moderate Hepatic Impairment (Cohort B) | Part 1: Severe Hepatic Impairment (Cohort C) | Part 1: Healthy Volunteers (Cohort D) | Part 2: Mild Hepatic Impairment Cohort | Part 2: Moderate Hepatic Impairment Cohort | Part 2: Healthy Volunteers Cohort | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 8 | 8 | 8 | 15 | 4 | 7 | 7 | 57 |
| Child-Pugh total scores(points) | Part 1: Mild Hepatic Impairment (Cohort A) | Part 1: Moderate Hepatic Impairment (Cohort B) | Part 1: Severe Hepatic Impairment (Cohort C) | Part 1: Healthy Volunteers (Cohort D) | Part 2: Mild Hepatic Impairment Cohort | Part 2: Moderate Hepatic Impairment Cohort | Part 2: Healthy Volunteers Cohort | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 5.38 ± 0.518 | 8.25 ± 0.886 | 11.50 ± 1.512 | — | 5.75 ± 0.5 | 7.71 ± 0.756 | — | 7.94 ± 2.25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2020 to primary completion in Mar 2022, 25 months.
Results were first posted in Aug 2024, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Galmed Research and Development, Ltd.